子宮内膜がんの世界市場-2023年～2030年

市場概要

子宮内膜がんの世界市場は、2022年に187億米ドルに達し、2030年には273億米ドルまで成長すると予測されています。世界の子宮内膜がん市場は、予測期間中（2023-2030年）に4.9%のCAGRを示すと予測されています。

市場力学

研究活動の活発化が子宮内膜がん市場の成長を牽引

製品認可の増加は、予測期間における世界の子宮内膜がん市場の成長を促進すると予想されます。例えば、2023年2月、欧州委員会は、成人の血友病Bの治療を適応とする1回限りの遺伝子治療薬であるHemgenix（etranacogene dezaparvovec）を条件付きで承認しました。Hemgenixは、主にuniQure社によって設計され、インヒビターの記録がない極度および比較的極度の血友病Bの成人に対して承認されました。ヘムジェニックスは、欧州連合（EU）の全加盟国に加え、アイスランド、リヒテンシュタイン、ノルウェーの全加盟国において、患者が知っている血友病Bの遺伝子治療の第一人者です。

さらに、2023年2月、スイスの世界的ヘルスケア企業であるロシュは、欧州委員会とヘムリブラ（一般名：エミシズマブ）の欧州連合（EU）販売承認拡大に関する同意を取得しました。現在、第VIII因子インヒビターを使用しない血友病Aで、極端な出血表現型を伴う軽症の患者における出血発生の標準的な予防が添付文書に記載される見込みです。

認識を広める努力の増加は、世界の子宮内膜がん市場に成長機会をもたらすと期待されます

増加する研究資金イニシアティブは、今後数年間、世界の子宮内膜がんに有利な成長機会をもたらすと期待されています。例えば、2023年6月1日、国際婦人科がん協会とその患者擁護関連団体である国際婦人科がん擁護ネットワーク（IGCAN）は、世界中の患者擁護団体の協力を得て、様々なキャンペーンを通じて子宮体がんと子宮内膜がんの認知度を高める決意を発表しました。

予測期間中、治療費の高さが世界の子宮内膜がん市場の妨げになると予測されます

治療費の高さは、予測期間中の世界の子宮内膜がん市場の成長を妨げると予測されます。例えば、インドにおける子宮体がん治療の費用は、治療のグレードや病院によって、4000米ドルから6000米ドルと幅があります。

COVID-19影響分析

COVID-19の大流行と世界各国での封鎖により、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ戦争の影響分析

ロシア・ウクライナ戦争は、世界の子宮内膜がん市場に中程度の影響を及ぼすと考えられています。しかし、ロシア軍からの襲撃に耐え続けるウクライナの診療所は、死亡者数の増加と特定の医療補助に押されています。あらゆる種類の薬が不足しています。また、基本的な材料の輸出入の結果は、予測期間中に世界の子宮内膜がん市場の成長にわずかな影響を与えると予測されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 調査活動の活発化
    • 普及率の高まり
  • 抑制要因
    • 高コスト
  • 機会
    • 意識の高まり
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• がん肉腫
• 腺がん
• 扁平上皮がん
• その他

第8章 治療タイプ別

• 免疫療法
• 化学療法
• 放射線療法
• その他

第9章 エンドユーザー別

• 病院
• がんセンター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Pfizer
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Elekta AB
• AstraZeneca PLC
• AbilityPharma（Ability Pharmaceuticals, SL）
• GlaxoSmithKline
• Eisai Co., Ltd
• ARIAD Pharmaceuticals
• Novartis
• Karyopharm Therapeutics
• Bayer AG

第13章 付録

Market Overview

The Global Endometrial Cancer Market reached US$ 18.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 27.3 billion by 2030. The global endometrial cancer market is expected to exhibit a CAGR of 4.9% during the forecast period (2023-2030).

The key market players in this market include Pfizer, AbilityPharma (Ability Pharmaceuticals, SL), and GlaxoSmithKline among others.

Market Dynamics

Increasing Research Activities Drive The Growth Of The Endometrial Cancer Market.

Increasing product approvals are expected to drive the global Endometrial Cancers market growth in the forecast period. For instance, in February 2023, the European Commission conditionally authorized Hemgenix (etranacogene dezaparvovec), a one-time gene therapy indicated for the treatment of adults with hemophilia B. Hemgenix, primarily designed by uniQure, authorized for adults with extreme and relatively extreme hemophilia B without a record of inhibitors. It's the foremost gene treatment for hemophilia B known to patients throughout all European Union member states, plus Iceland, Liechtenstein, and Norway.

Moreover, in February 2023, Roche, a Swiss global healthcare corporation acquired the European Commission and consent for the expansion of the Hemlibra (emicizumab) European Union (EU) marketing authorization. The label is expected to currently contain the standard prophylaxis of bleeding outbreaks in individuals with hemophilia A without factor VIII inhibitors, who have mild conditions with an extreme bleeding phenotype.

The Increasing Efforts To Spread Awareness Are Expected To Present The Global Endometrial Cancer Market With Growth Opportunities.

The increasing research funding initiatives are expected to present global endomertial cancer with lucrative growth opportunities in the upcoming years. For instance, on June 1, 2023, the International Gynecologic Cancer Society and its patient advocacy associate, the International Gynecologic Cancer Advocacy Network (IGCAN) with help from patient advocacy organizations all over the globe announced its determination to raise awareness of uterine and endometrial cancer through various campaigns.

The High Cost of Treatment Is Estimated To Hamper The Global Endometrial Cancer Market During The Forecast Period.

The high cost of treatment is estimated to hamper the global endometrial cancer market growth in the forecast period. For instance, the cost of uterine cancer therapy in India varies from US$ 4000 - US$ 6000 based on the grade of therapy and the hospital.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine war is considered to carry a moderate mark on the global endometrial cancer market, as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids. There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of fundamental materials are predicted to have a small influence on the global endometrial cancer market growth in the forecast period.

Segment Analysis

The global endometrial cancer market is segmented based on type, therapy type, end-user and region.

Owing To The Increasing Positive Outcomes From The Immunotherapy Clinical Investigations The Segment Is Estimated To Hold About 34.9% Of The Global Market Share By 2030.

Immunotherapy for uterine (endometrial) cancer is an emerging domain of investigation and therapy, particularly for individuals with advanced cases. The increasing positive outcomes from immunotherapy for endometrial cancer are boosting segment growth. For instance, in March 2023, implementing immunotherapy to classic chemotherapy for first-line therapy of progressive or first repetition of endometrial cancer greatly enhances progression-free survival (PFS) analogized to chemotherapy independently, with a favorable premature sign of enhanced overall survival (OS). These clinically significant outcomes from the Phase 3 RUBY investigation (ENGOT-EN6-NSGO/GOG3031) are the foremost validation of the advantages of immunotherapy in this patient population and were conveyed at the European Society for Medical Oncology Virtual Plenary on 27 March 2023.

Geographical Analysis

Europe Estimated to Hold 27.4% of the Market Share Owing to the Growing Endometrial Cancer Prevalence in this Region.

Owing to the growing cases of uterine cancers and the presence of various organizations spreading awareness and funding research activities in uterine cancer in Europe, the region is estimated to hold the second largest share of the global market accounting for about 27.4% of the total market. For instance, uterine cancer is the fourth highly typical cancer in females in the UK, accounting for 5% of all new gynecological cancer patients. About 9,400 fresh patients are analyzed annually, leading to the death of 2,300 females. The majority of cases appear in the seventh and eighth decades of life. Since the earlier 1990s, the incidence of uterine cancer has grown by 55% in the UK.

Moreover, associations like GRACE Charity desire to support the locally founded investigation into gynecological cancers such as ovarian, uterine, cervical, and vulvar cancer, primarily at the University of Surrey in Guildford, and within the Gynecology Department and spreading awareness about the condition are also contributing to the growth.

Competitive Landscape

The major global players in the endometrial cancer market include: Pfizer, AbilityPharma (Ability Pharmaceuticals, SL), Elekta AB, GlaxoSmithKline, Eisai Co., Ltd., ARIAD Pharmaceuticals, Novartis, AstraZeneca PLC, Karyopharm Therapeutics, and Bayer AG among others.

Why Purchase the Report?

• To visualize the global endometrial cancer market segmentation based on type, therapy type, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of endometrial cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global endometrial cancer market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Therapy Type
• 3.3. Snippet by End-user
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Research Activities
    • 4.1.1.2. Growing Prevalence
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost
  • 4.1.3. Opportunity
    • 4.1.3.1. Growing Awareness
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Carcinosarcoma *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Adenocarcinoma
• 7.4. Squamous cell Carcinoma
• 7.5. Others

8. By Therapy Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 8.1.2. Market Attractiveness Index, By Therapy Type
• 8.2. Immunotherapy *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Chemotherapy
• 8.4. Radiation Therapy
• 8.5. Others

9. By End-user

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.1.2. Market Attractiveness Index, By End-user
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cancer Centers
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan

Australia

• 10.5.6.4. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Pfizer*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Elekta AB
• 12.3. AstraZeneca PLC
• 12.4. AbilityPharma (Ability Pharmaceuticals, SL)
• 12.5. GlaxoSmithKline
• 12.6. Eisai Co., Ltd
• 12.7. ARIAD Pharmaceuticals
• 12.8. Novartis
• 12.9. Karyopharm Therapeutics
• 12.10. Bayer AG

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us